海思科获得创新药HSK39297片新适应症《药物临床试验批准通知书》

Core Viewpoint - The company has received approval from the National Medical Products Administration for clinical trials of HSK39297 tablets, a new drug for age-related macular degeneration (AMD) with independent intellectual property rights [1] Group 1: Drug Development - HSK39297 tablets are independently developed by the company and target age-related macular degeneration [1] - Preclinical research indicates that the drug has a clear target, definite efficacy, and good safety profile, making it a promising small molecule drug [1] - The drug is expected to have a high benefit/risk ratio in clinical applications, indicating a broad clinical application prospect [1] Group 2: Market Potential - HSK39297 tablets aim to address the current shortage of effective clinical treatments for AMD, potentially becoming a viable therapeutic option [1]